Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
European Journal of Neurology2022Vol. 29(8), pp. 2473–2480
Citations Over TimeTop 10% of 2022 papers
Modar Khalil, David Moreno‐Ajona, Maria Dolores Villar‐Martínez, Fiona Greenwood, Jan Hoffmann, Peter J. Goadsby
Abstract
Our real-world data with erenumab demonstrate it is effective and well tolerated in managing patients with chronic migraine in a tertiary care setting.
Related Papers
- → Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine(2017)67 cited
- → Efficacy and Safety of Fremanezumab in Patients with Migraine: Real-World Evidence in a Private Neurological Center(2022)1 cited
- → Efficacy and Safety of CGRP Monoclonal Antibodies for the Prevention of Migraine Compared with Placebo: A Systematic Review and Meta-Analysis(2020)2 cited
- → Galcanezumab in the prophylaxis of migraine(2020)
- → 6ER-024 Comparison of reductions in monthly migraine days between new small molecule cgrp receptor antagonists (gepants) and monoclonal antibodies targeting cgrp/cgrp receptor(2023)